Target intelligence / Profile preview

Metalloenzyme (Human)

Molecular classification
Enzyme, Metalloprotein
01

Overview

Human metalloenzymes are a superfamily of enzymes that require one or more tightly bound metal ions (such as zinc, iron, copper, manganese, nickel, cobalt, or molybdenum) for their catalytic activity or structural integrity. These enzymes are essential for a vast array of biological processes, including redox chemistry (e.g., cytochrome P450s, superoxide dismutase), hydrolysis (e.g., matrix metalloproteinases, carbonic anhydrase), and DNA/protein modification (e.g., zinc finger nucleases). Metalloenzymes are frequent drug targets in many disease settings, but the term "human metalloenzymes" encompasses many distinct enzymes—each with specific functions, disease relevance, and therapeutic challenges[1][2][4][5][6][7]. This term is *not* a precise molecular target but a broad category. For drug discovery, diagnosis, or detailed research, it is necessary to refer to individual metalloenzymes (e.g., "Matrix metalloproteinase 9," "Carbonic anhydrase II," "Zinc finger protein 1") rather than this collective label.

Other names
Metal-dependent enzymeMetal-activated enzyme
02

Mechanism of action

Chelation/inhibition of the active site metal ion Competitive inhibition at the substrate binding site Allosteric modulation via metal ion interaction Disruption of metal ion delivery or incorporation

03

Biological functions

Catalysis of redox reactionsHydrolytic activity (e.g., proteolysis, CO₂ hydration)Electron transferSubstrate recognition and bindingStructural support for protein foldingRegulation of gene expression (e.g., zinc fingers)
04

Disease associations

Cancer (e.g., matrix metalloproteinases in metastasis)Inflammation (e.g., metalloproteinases in tissue remodeling)Neurodegenerative diseases (e.g., superoxide dismutase in ALS)Cardiovascular disease (e.g., angiotensin-converting enzyme in hypertension)Infection (e.g., metallo-beta-lactamases in antibiotic resistance)Other
05

Safety considerations

Off-target inhibition, leading to interference with essential metal homeostasisToxicity due to metal ion displacement or depletion (e.g., zinc, copper)Impact on multiple physiological pathways due to broad rolesImmunogenicity of some metalloenzyme-targeting drugs
06

Interacting drugs

Matrix metalloproteinase inhibitors (e.g., marimastat, batimastat)

5 more in the full profile.

07

Biomarkers

Serum/plasma levels of specific metalloenzymes (e.g., MMP-9 in cancer, cardiac troponin metalloproteinases)Enzymatic activity assays for individual metalloenzymesMetal ion concentration in tissues as indirect markers

Beyond the preview

Go deeper on Metalloenzyme (Human).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metalloenzyme (Human).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call